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Abstract
Background: Juvenile idiopathic arthritis (JIA) is the most common childhood rheumatic illness. There is little
published data on the financial burden of this illness. The primary objective of this study was to determine the
annual costs borne by families of a child with JIA living in Nova Scotia (NS).
Methods: All families in NS with a child followed in the Pediatric Rheumatology Clinic at the Izaak Walton Killam
Health Centre (IWK) in 2009 were mailed a self-report questionnaire. The questionnaire evaluated disease related
costs, gross household income and perceived financial burden. Dillman's method was used to optimize return rates.
Descriptive statistics were used to summarize results. Spearman’s correlation coefficient was used to assess the
relationship of distance from the IWK and cost. The Mann–Whitney U test was used to compare median costs
between groups.
Results: Of 172 possible respondents, we received 54 completed questionnaires and 11 blank questionnaires
(overall response rate 31.4%). Approximately one third (35.9%) of parents rated the financial burden as moderate or
large and 36% rated financial resources available as poor. The median annual total cost per patient was $619.50
CAD (range 0, $5535) which was a median 0.7% (range 0, 37%) of gross household incomes. The largest expense
for families was visit related costs. There was not a significant relationship between total annual costs and distance
from the IWK (rs = 0.18, P = 0.2). Families of a child with oligoarthritis had significantly lower costs than the families
of a child with another subtype of JIA ($359.00 CAD vs. $877.00 CAD, P = 0.02).
Conclusions: The costs associated with having a child with JIA in NS are on average modest, but may be
considerable for some families. Oligoarticular JIA is associated with smaller costs. Many families perceive the burden
to be at least moderate and the availability of financial resources to be poor. Supports should be targeted to those
families most in need.
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Background
Juvenile idiopathic arthritis (JIA) is the most common
rheumatic illness affecting children with approximately 1
in 1000 children having one of 7 categories [1]. While
there can be considerable variation in number of joints
affected, disease severity and non-articular features, all
children with JIA have a chronic illness which requires
ongoing treatment and medical monitoring. This results
in financial costs to families with JIA.
The Canadian health care system bears a significant
portion of the medical costs, particularly physician and
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institution-based services. However, costs related to prescription medications, assistive devices and physiotherapy are often not included. Not all families have health
insurance (whether private or government administered)
to assist with these additional costs. There are also other
non-medical costs which can add to the financial burden.
These include costs associated with visits for medical
care (travel, parking, meals, accommodations) and loss of
paid work. The cost to families in order to provide their
children with the recommended standard of care is
unknown. However, anecdotal experience suggests that
the burden for some families can be considerable.
The goal of this study was to determine the annual
out-of-pocket medical and related non-medical expenses
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borne by Nova Scotian families who have a child with
JIA. We also assessed perceptions of financial burden
and financial support for these same families.

Methods
Study design and population

The Izaak Walton Killam Health Centre (IWK), located
in Halifax, Nova Scotia, provides tertiary sub-specialist
pediatric care to children in Nova Scotia (NS), New
Brunswick and Prince Edward Island, Canada. This hospital
is the only source of pediatric rheumatology care in these
provinces, and most children with JIA are followed here.
A questionnaire was created to estimate the annual
out-of-pocket costs borne by families as a result of their
child’s JIA (Additional file 1: Appendix). To ensure content
validity, members of the allied health care team and a
convenience sample of selected families followed in the
clinic reviewed the questionnaire. The questionnaire
was mailed to all families in NS with a child followed
in the Pediatric Rheumatology Clinic at the IWK for a
diagnosis of JIA [1]. Families with more than one child
affected by JIA were excluded as were children with
JIA and another concurrent, unrelated chronic disease.
A parent or primary caregiver was asked to complete
the paper-based questionnaire and mail it back to the
investigators in a pre-stamped envelope. The Dillman
method was used to optimize response [2]. Specifically,
all potential participants were mailed a card indicating
that they would be receiving a questionnaire. The
questionnaire was mailed 1 week later, with a reminder
mailed 2 weeks after that. All mailings included a phone
number for additional information or to opt out of future
mailings. A chart review was also completed to document
JIA category, medication use, number of appointments for
clinics, medication infusions, and joint injections, and the
number and duration of admissions.
Approval from the Research Ethics Board at the IWK
was obtained. Return of the questionnaire constituted
implied consent for participation in this research study.
Outcomes

The questionnaire included demographics, insurance
status, distance from rheumatology clinic, and detailed
questions about medical and related non-medical out-ofpocket costs. Families were also asked to estimate cost of
lost paid work. All questions referred to the calendar year
2009, and all costs were given in Canadian dollars. All costs
that were paid by the health care system or health insurance were excluded. The following definitions were used:
1. Medical costs included costs of medications, splint
material, assistive devices, and physiotherapy.
2. Non-medical costs included those costs which were
not medical in nature, but were incurred in order
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that the child with arthritis received appropriate
care. These included costs related to visits for
outpatient clinics (rheumatology or other specialists,
locally or at the IWK), medication infusions and
hospital admissions. Costs for these visits included
transportation, parking, accommodations, childcare
for other children, and communications related to
the visit. Non-medical costs also included those
related to home adaptations and driving their child
to school.
3. Finally, cost due to loss of paid work was defined as
the loss of pay due to time away from work for
reasons related to their child’s arthritis. This could
be either or both parents.
Gross annual household income was collected to
allow calculation of costs related to their child’s JIA as
a proportion of the family income. Perceptions of the
financial burden associated with having a child with JIA
and access to financial resources were also evaluated in
the questionnaire using ordered response categories.
Analysis

Descriptive statistics were calculated for all parameters of
the questionnaire. For consistency with previous literature,
costs were summarized as medical, non-medical and those
related to loss of paid work. The total cost was also compared to the household income per patient to determine
the proportion of income lost. Spearman correlation coefficients were calculated to evaluate the relationship between
costs and distance from the IWK. For this analysis, distance
was estimated using travel time to the IWK, as the data
was more complete than for actual distance.
The Mann–Whitney U-test was used to compare costs
for between groups of children. Given the small number
of patients, these analyses were considered exploratory.

Results and discussion
Of 172 questionnaires mailed out, 5 were returned
unopened due to incorrect addresses. Fifty-four (31.4%)
were returned completed, and another 11 (6.6%) were
returned blank or the family called to decline participation.
Mothers completed 81.8% of the questionnaires.
Participant characteristics are summarized in Table 1.
All JIA categories were represented and most patients
were taking medications. Most patients lived at least 100
km from the IWK and/or 60 minutes away. Nearly all
patients had some form of health insurance support.
The perceived financial burden was rated as either large
or moderate by 35.9% of respondents. Perceived access
to resources to help pay for the costs was rated as poor
by 36% of parents.
The median number of trips to the IWK for clinic
appointments in 2009, excluding trips for joint injections
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Table 1 Characteristics of study participants (N = 54)
Age (years) (median, range)

14 (5,20)

Gender (Female: Male)

32 (59%):22 (41%)

JIA Category
Oligoarticular-persistent

13 (24%)

Oligoarticular-extended

8 (15%)

Polyarticular, RF negative

8 (15%)

Polyarticular, RF positive

1 (2 %)

Systemic

7 (13%)

Enthesitis-related

8 (15%)

Psoriatic

7 (13%)

Undifferentiated

2 (4%)

No medications

14 (26%)

NSAIDs

30 (57%)

DMARDs

26 (49%)

Current Medications (N = 53)

Corticosteroids
Biologics
Distance from IWK Health Centre (km) (median, range) (N = 39)

1 (2%)
7 (13%)
35 (4, 500)

Greater than/equal to 100 km N (%)

30 (77%)

Driving time to IWK Health Centre (min) (median, range) (N = 54)

47.5 (15, 300)

Greater than/equal to 60 minutes N (%)

26 (48%)

Gross Family income (median, range)

$70000 ($2500, $175000)

Supplemental Health Insurance (N = 53)
Employer Plan

21 (40%)

Personal Private

26 (49%)

Social Assistance

1 (2%)

None

5 (9%)

Perceived Financial Burden (N = 53)
Large

1 (2%)

Moderate

18 (34.0%)

Minimal

24 (45.3%)

None

10 (18.9%)

Perceived Availability of Resources (N = 50)
Excellent

8 (16%)

Good

14 (28%)

Fair

10 (20%)

Poor

18 (36%)

JIA, juvenile idiopathic arthritis; IWK, Izaak Walton Killam Health Centre.

or medication infusions, was 4 (range 0–27). Six children
had joint injections at the IWK (once for 4 children,
twice for 2 children). Two children also came to the
IWK for regular infusion (10 visits and 13 visits).
Data on annual costs for 2009 are presented in Table 2.
The median total annual cost per patient was $619.50
(range 0-$5,535.00), which was a median of 0.7%
(range 0-37%) of the household income. Non-medical
costs, primarily related to visits locally and at the IWK,

were the largest cost. Medical costs, primarily medications,
were a relatively small component of the total costs.
The median cost per IWK clinic visit was $45.00
(range 0-$762.00). The median cost per clinic visit outside
the IWK was $15.00 (range 0-$100.00). Due to small
numbers, similar results were not calculated for emergency,
infusion or joint injection visits.
There was no significant correlation between distance
from the IWK and annual total costs (rs = 0.18, P = 0.2).
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Table 2 Annual costs related to having a child with
juvenile idiopathic arthritis (in Canadian Dollars)
Mean
(standard deviation)

Median (range)

179.30 (328)

0 (0, 1680.00)

1.72 (13)

0 (0, 93.00)

Annual Medical Costs
Medication
Physiotherapy
Aids/splint materials

48.92 (98)

0 (0, 350.00)

229.95 (343)

122.50 (0, 1680.00)

IWK Visit Costs

326.91 (396)

226.25 (0, 2286.00)

Peripheral Visit Costs

116.67 (175)

50.50 (0, 1000.00)

Total Annual Visit Costs

443.58 (427)

414.75 (0, 2286.00)

Home Adaptations/
Driving to School

34.17 (217)

0 (0, 1600.00)

Total

477.75 (519)

436.25 (0, 2685.00)

Total
Annual Non-Medical Costs

Annual Loss of Paid Work

354.81 (712)

0 (0, 2600.00)

Total Annual Costs

1062.50 (1227)

619.50 (0, 5535.00)

Percent of Gross
Household Income

2.5% (5.5)

0.7% (0, 37%)

There was a moderate correlation between distance
from the IWK and total annual visit costs to the IWK
(rs = 0.30, P = 0.03).
In exploratory analyses, children with oligoarticular
JIA had a median annual total cost of $359.00 (range
$32-1205.00) while those with all other categories
combined had a median annual total cost of $877.00
(range $0-5535.00, P = 0.02). Children living more than
60 minutes from the IWK had a mean annual total cost
of $893.50 (range $0-5535.00) while those living closer
than 60 minutes away had a mean annual total cost of
$460.38 (range $0-3284.00, P = 0.07).
Families who rated the financial burden of having a child
with JIA as being either large or moderate had a median
annual total cost of $1205.00 (range $120-5036.00)
compared to $474.88 (range $0-5535, P = 0.006) for
those who rated it as minimal or none. The proportion
of gross family income represented by the total costs of
JIA were 3.0% (large or moderate burden) and 0.5%
(minimal or no financial burden) (P = 0.002).

Conclusions
This study reports the financial costs borne by families
of children with JIA living in Nova Scotia in 2009. We
have shown that costs vary dramatically between households. The majority of costs were related to medical visits,
followed by costs related to time away from paid work.
Medical costs formed a relatively small component of the
total costs. We found that disease category was associated
with cost, with oligoarticular JIA resulting in smaller costs

than other types. We also saw a trend towards increasing
costs with increasing distance from the IWK.
On average, total costs were relatively modest. However,
our data show 2 important related findings. First, while
costs were not large for most families, some families
experienced total costs as high as 37% of their gross
household income. Second, almost 36% of respondents
reported their perception of the financial burden as being
either moderate or large. It could be argued that having
nearly 2/3 of families experiencing mild or no financial
burden is a success of the health care system. However,
we believe that we can do better, and our study highlights
financial burden as an important issue for many families,
and one that should be monitored in pediatric rheumatology clinics. Given that 36% of respondents also considered
resources to assist with costs to be poor, further attention is
needed to this issue.
We expected that distance from the IWK Health
Centre would be an important factor impacting cost.
Given the relatively widespread, rural population of
Nova Scotia, this is an important issue in our clinic.
However, our data showed no significant correlation
between distance and total cost and only a moderate
correlation between distance and IWK specific visit
costs. There was a non-significant trend for families
living more than 60 minutes away to have higher costs.
The explanation for this lack of a relationship is unclear.
It may be that some costs are unrelated to distance
(including all medical costs, and some visit costs, such
as parking). Additionally, it is possible that follow-up
frequency is influenced by distance for children with
similar JIA. It is important that all children receive optimal
care and follow-up, regardless of residence. Our data was
not adequate to investigate this question, but this is an issue
which bears additional study. We did note that costs associated with IWK visits were higher than those associated with
local visits ($45.00 vs $15.00), suggesting that distance had
at least some impact.
Comparing our results to previous work has some
important challenges. The costs associated with health
care and the financial responsibility for these costs varies
considerably between countries and between regions
within countries. This makes extrapolation of research
conducted in one country or region to another country
or region difficult. Health care costs can also vary
considerably over time, as new medications become
available or health care coverage changes. For example, in
JIA the advent of biologic medications has the potential to
markedly influence medical costs.
Despite these limitations, some research in this area
has been conducted. Allaire et al. reported costs for 70
families with a child with juvenile rheumatoid arthritis
(JRA) from the New England area in 1989 [3]. Total yearly
family out-of-pocket expenses were $1525 USD ($1818
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CDN; all non-Canadian dollar costs converted to Canadian
dollars for comparison using the mean conversion rate for
year of publication or year of data collection if available).
This included $708 USD for medical costs (professional
services, investigations, medications and casts/splints),
$488 USD for non-medical costs (transportation, meals,
lodging, child-care, home adaptations) and $328 USD for
loss of paid work. This total represented 5% of the annual
family income. They also found that children with systemic
JRA had greater costs than either the polyarticular or
pauciarticular JRA groups.
Minden et al. reported on a group of 215 adults in
Berlin with a history of JIA (mean age 23 years, mean
disease duration 17 years) [4]. They found that outof-pocket costs in 1999 were €77 ($117 CDN) of which
€66 was medical (medications) and €11 was non-medical
(transportation). They determined that the mean cost
due to lost paid work was €1571. They also found that
patients with rheumatoid factor positive polyarticular
JIA and extended course oligoarticular JIA, as well as those
with greater disease activity or functional limitations, had
the highest costs. The authors point out that only 50% of
these patients had seen a rheumatologist in the preceding
12 months and 1/3 were rated as having insufficient
specialized care by the investigators. Given the lack of
contact with care-providers, it is not clear how to interpret
these results.
Bernatsky et al. compared 155 children with JIA to
181 outpatient clinic controls without JIA in Montreal and
Vancouver, Canada in 2005 [5]. This study determined
total direct medical costs, but did not distinguish those
borne by the health-care system and those borne by the
family. However, they did report an annual loss of paid
work by caregivers of $1241 CDN. They also noted a direct
relationship between total direct costs and disease activity.
Minden et al. studied 369 children with JIA from a
national German database, with costs estimated for 2003
[6]. While this study focused on the overall economic
impact of JIA on the health care system, they found that
families spent €223 ($343 CDN) per year. This consisted of
€54 for medical costs (medications, treatments) and €169
for non-medical costs (€132 for transportation, remainder
for telephone, home alterations, childcare). They reported
costs due to lost paid work to be €270 per year. Finally, as
with other investigators, they found that costs varied significantly between JIA categories, with rheumatoid factor
positive polyarticular JIA having the highest costs, and that
costs increased with increasing disease duration, disease
severity, pain, functional limitations, uveitis and delays to
first pediatric rheumatology appointment.
Thornton et al. studied 297 children newly diagnosed
with JIA at 4 UK hospitals [7]. While the year of study
entry/diagnosis was not provided, costs were extrapolated
to 2005. This study calculated primarily direct medical
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costs to the health care system and did not address the
issue of patient or family out-of-pocket costs.
Finally, Yucel et al. studied 100 children with JIA in
Turkey in 2008 [8]. Due to the nature of the health care
system in Turkey at the time of the study, virtually all
medical costs (medications, investigations, physicians) were
not paid by families. However, the authors did find that
families paid €188 ($324 CDN) per year in non-medical
costs (transportation, accommodations) and an additional
€81 ($140 CDN) per year in costs due to lost paid work.
In our study, we found that costs were higher than
reported by most investigators, other than Allaire et al. [3].
However, costs due to loss of paid work were less than
reported by other investigators (median $0, mean $354.81).
These differences may reflect differences in our population,
such as a more dispersed rural population or more parents
engaged in unpaid work (either in the home or seasonal
work such as fishing). The relationship of these differences
to financial burden and the ability to achieve good care
warrants further investigation.
Only 13% of patients in this study were treated with
biologics. Over time, this proportion is increasing. However,
the impact on costs to families is not easy to predict. Given
the expense of these medications, it is unlikely that
most families could afford them without insurance or other
support. In our clinic, we have not prescribed biologics
where families have not had some form of coverage. Even
with insurance, families may have co-pay charges which
could be considerable. Biologic therapy could also have an
impact on visit costs, as some of the biologic treatments
require infusions at the hospital, clinic or infusion centre.
These evolving costs will require monitoring over time.
As with all questionnaire-based research, this study
needs to be interpreted with certain limitations in mind.
First, we experienced a relatively modest response rate.
This is not uncommon in this type of research, but does
raise questions about how well respondents represent
the overall population. The JIA category distribution of
respondents is similar to our overall clinic population. If
there is a bias introduced here, it is difficult to predict in
which direction it may operate. It is possible that some
families with significant financial concerns would be
more likely to respond. However, it is also possible that
those same families would be less likely to respond due
to concerns about being stigmatized. A second limitation is recall bias. To minimize this, a chart review was
completed to supplement and confirm data from the
questionnaire, especially the number of visits to the
IWK. Finally, costs are specific to location and health
care system. This limits the direct applicability of our
results to other jurisdictions. However, our overall findings are likely to be similar to other Multidisciplinary
Rheumatology Clinics that provide services to large
geographic areas.
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The impact of the financial burden on families of children with JIA is unknown. Beyond psychosocial stressors
in the home, concern has been raised about the effect
on outcomes. A prospective cohort study in a tertiary
care center in the United States showed a significantly
higher physical disability rate and lower health-related
quality of life in children with JIA who had Medicaid or
other similar state-programs for low-income families
compared to those children with JIA who had insurance
coverage [9]. This study suggests that it may be important
to identify families who are struggling financially to
optimize their child’s medical care.
We conclude that while the overall costs associated
with having a child with JIA in Nova Scotia are modest
for many families, the financial burden can be significant
for some and may become a barrier to the provision of
appropriate care. Many families perceive the financial
burden to be high and the access to resources to be poor.
Assistance in the form of targeted programs to aid families
with the greatest costs should be considered. The impact
of the financial burden on outcomes in children with JIA
is unknown and warrants further evaluation.
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